Celcuity Inc. Common Stock
CELC
$144.98
+15.38%
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumors, operating within the competitive oncology sector. Its distinct identity is built on its lead candidate, gedatolisib, a kinase inhibitor targeting the PI3K/AKT/mTOR pathway with a differentiated mechanism aimed at comprehensive inhibition. The current investor narrative is overwhelmingly centered on the high-stakes FDA review and commercial potential of gedatolisib, particularly for HR+/HER2- breast cancer, driving extreme stock volatility and speculative interest as the company transitions from a pre-revenue R&D entity to a potential commercial-stage biotech.…
CELC
Celcuity Inc. Common Stock
$144.98
Related headlines
CELC 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celcuity Inc. Common Stock's 12-month outlook, with a consensus price target around $188.47 and implied upside of +30.0% versus the current price.
Average Target
$188.47
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$116 - $188
Analyst target range
Analyst coverage is limited, with only 2 analysts providing estimates, indicating this is a stock with higher volatility and less efficient price discovery typical of small/mid-cap, clinical-stage biotechs. The wide range in their revenue estimates, from a low of $945.3 million to a high of $2.16 billion, signals extremely high uncertainty and divergent views on the commercial potential of gedatolisib, with the high target likely pricing in strong market adoption and the low target reflecting more conservative penetration or competitive risks.
Bulls vs Bears: CELC Investment Factors
The bull case for CELC is powered by explosive price momentum, strong institutional conviction, and the multi-billion dollar revenue potential of its lead drug candidate. The bear case is grounded in the stark reality of a pre-revenue company with heavy losses, extreme valuation, and total dependency on a binary clinical outcome. Currently, the bullish momentum has stronger short-term evidence, as reflected in the 1063% annual gain and institutional accumulation. However, the single most important tension in the investment debate is the disconnect between the current $5.24 billion market capitalization—which prices in near-certain commercial success—and the company's present financial reality of $0 revenue and -$154 million in annual cash burn. The resolution of this tension, via either successful FDA approval and commercialization or clinical failure, will determine ultimate investment returns.
Bullish
- Massive 1-Year Price Momentum: The stock has surged 1063.43% over the past year, reflecting extreme market optimism for its lead drug candidate, gedatolisib. This momentum is supported by recent institutional buying, including a $170 million fund bet, signaling high conviction in the upcoming FDA catalyst.
- Strong Institutional Conviction: Recent news highlights major funds making substantial investments, with one creating a top-two position. This institutional backing provides validation and can offer support during volatile periods, though it doesn't eliminate the underlying binary risk.
- Robust Balance Sheet Liquidity: With a current ratio of 10.55, the company has ample short-term assets to cover liabilities, providing a financial runway to fund operations through key clinical milestones. This reduces near-term solvency risk despite heavy R&D spending.
- Significant Analyst Revenue Potential: Analyst estimates project future revenue averaging $1.43 billion, with a high target of $2.16 billion, implying a substantial commercial opportunity if gedatolisib gains approval. This potential justifies the current $5.24 billion market cap for speculative investors.
Bearish
- Pre-Revenue with Heavy Losses: The company reported $0 revenue and a net loss of -$50.97 million in Q4 2025, with a trailing twelve-month free cash flow of -$153.53 million. This deep cash burn necessitates continued external financing, diluting shareholders until commercialization.
- Extreme Valuation on Negative Metrics: Traditional valuation metrics are inapplicable (PS ratio of 0), and the trailing PE has expanded to -29.6 from -3.22 in Q2 2025. The $5.24 billion market cap prices in near-perfect success, leaving massive downside if clinical results disappoint.
- High Leverage and Negative Profitability: A debt-to-equity ratio of 1.94 indicates significant leverage, while ROE is -176.06% and ROA is -30.24%. These metrics highlight financial strain and inefficiency in converting assets to earnings, a critical vulnerability for a clinical-stage company.
- Price Near 52-Week High, Risk of Pullback: Trading at $125.65, the stock is 97% of the way to its 52-week high of $129.09, following a 1063% annual gain. This overextended technical position makes it highly susceptible to a sharp correction on any negative news or failed catalyst.
CELC Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +1063.43%. With a current price of $125.65, it is trading near the top of its 52-week range, approximately 97% of the way from its 52-week low of $9.51 to its high of $129.09, indicating extreme momentum but also positioning it at risk of a sharp pullback from overextended levels. Recent momentum shows signs of consolidation within the uptrend, with a 1-month gain of +11.26% and a 3-month gain of +14.83%, which, while positive, represents a significant deceleration from the explosive longer-term trend, suggesting the stock may be digesting its massive gains and searching for a new catalyst. Key technical levels are clear, with immediate resistance at the 52-week high of $129.09 and support far below near the $9.51 low; a breakout above resistance would signal renewed bullish conviction, while a breakdown could trigger a steep correction, though the stock's beta of 0.422 indicates it has been significantly less volatile than the broader market during this specific period, which is unusual for a biotech and may reflect a shift in trading dynamics as it approaches a binary event.
Beta
0.09
0.09x market volatility
Max Drawdown
-27.7%
Largest decline past year
52-Week Range
$10-$151
Price range past year
Annual Return
+1230.1%
Cumulative gain past year
| Period | CELC Return | S&P 500 |
|---|---|---|
| 1m | +28.7% | +9.5% |
| 3m | +30.6% | +4.1% |
| 6m | +94.4% | +6.0% |
| 1y | +1230.1% | +26.7% |
| ytd | +44.2% | +5.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CELC Fundamental Analysis
The company has no commercial revenue, reporting $0 in the most recent quarter (Q4 2025), which is consistent with its clinical-stage status; the growth narrative is entirely forward-looking, hinging on the success of its Phase 3 trials, with analyst estimates projecting future revenue averaging ~$1.43 billion. Profitability is deeply negative, with a net income of -$50.97 million and an EPS of -$0.96 for Q4 2025, and gross and operating margins of 0%, reflecting heavy investment in research and development, which totaled $37.63 million in the same quarter as the company burns cash to advance its pipeline. The balance sheet shows a strong current ratio of 10.55, indicating ample short-term liquidity, but a debt-to-equity ratio of 1.94 points to significant leverage, while trailing twelve-month free cash flow is deeply negative at -$153.53 million, underscoring the company's dependence on external financing to fund operations until it can potentially generate product sales.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-153529000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CELC Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio; however, the reported PS ratio is 0 due to zero current revenue, making traditional multiples inapplicable and highlighting that valuation is entirely based on future potential rather than current financials. Peer comparison using standard multiples is not meaningful, as the company lacks the revenue and profitability metrics that define typical biotech valuations; instead, its $5.24 billion market cap reflects speculative premium pricing for the anticipated commercial success of gedatolisib. Historical context shows the stock's own trailing PE ratio has expanded dramatically to -29.6 as of the latest data, from much less negative levels in prior quarters (e.g., -3.22 in Q2 2025), indicating the market is applying a significantly higher valuation to its ongoing losses, which aligns with increased optimism around clinical catalysts but also signifies extreme risk if those catalysts fail to materialize.
PE
-29.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -26x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-30.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and stem directly from the company's clinical-stage status. CELC has no commercial revenue, reporting $0 in the latest quarter, and is burning cash at an alarming rate with a trailing twelve-month free cash flow of -$153.53 million. Net losses deepened to -$50.97 million in Q4 2025, and while the current ratio of 10.55 provides a liquidity buffer, the debt-to-equity ratio of 1.94 indicates significant leverage. The company's survival and growth are entirely dependent on the success of a single drug candidate, gedatolisib, creating extreme revenue concentration risk. Any delay or failure in clinical trials would immediately threaten its financial viability, forcing further dilutive equity raises or debt issuance.
Market & Competitive Risks are amplified by the stock's speculative valuation and sector dynamics. With a PS ratio of 0 and a trailing PE of -29.6, the $5.24 billion market cap implies flawless execution and blockbuster sales. This leaves the stock vulnerable to severe valuation compression if clinical data is merely good instead of exceptional, or if sector sentiment towards high-risk biotechs sours. The oncology space is intensely competitive, and gedatolisib faces established and emerging therapies for HR+/HER2- breast cancer. Despite a beta of 0.422 suggesting lower-than-market volatility recently, the stock's 1063% annual gain and proximity to its 52-week high make it a prime candidate for profit-taking and heightened volatility around binary events, as seen in recent price swings.
Worst-Case Scenario involves a clinical setback for gedatolisib, such as disappointing Phase 3 data or an FDA rejection. This would trigger a collapse in the speculative premium, leading to a rapid unwind of the 1063% annual gain. Institutional investors, who have recently built large positions, would likely exit en masse. The realistic downside could see the stock re-test its fundamental value as a cash-burning R&D entity, potentially falling towards its 52-week low of $9.51. From the current price of $125.65, this represents a catastrophic loss of approximately -92%. A more measured, yet still severe, bear-case target could align with a 70-80% drawdown from current levels, similar to the stock's recent maximum drawdown of -27.68% but on a much larger scale, resulting in a loss of -$88 to -$100 per share.